Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19

Ryoma Moriya; Naoki Kamihata; Yoshikazu Niwa; Hisashi Kako; Hideaki Takahashi; Yutaro Kimura; Yoshiko Shigeyasu; Tetsuya Tsukamoto; Naozumi Hashimoto; Kazuyoshi Imaizumi

doi:10.1016/j.resinv.2024.03.002

Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19

Ryoma Moriya, Naoki Kamihata, Yoshikazu Niwa, Hisashi Kako, Hideaki Takahashi, Yutaro Kimura, Yoshiko Shigeyasu, Tetsuya Tsukamoto, Naozumi Hashimoto, Kazuyoshi Imaizumi

Research output: Contribution to journal › Article › peer-review

Abstract

A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients. Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.

Original language	English
Pages (from-to)	438-441
Number of pages	4
Journal	Respiratory Investigation
Volume	62
Issue number	3
DOIs	https://doi.org/10.1016/j.resinv.2024.03.002
Publication status	Published - 05-2024

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.resinv.2024.03.002

Cite this

@article{89aa294f7b744ada84d69b4b178d77fe,

title = "Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19",

abstract = "A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients. Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.",

author = "Ryoma Moriya and Naoki Kamihata and Yoshikazu Niwa and Hisashi Kako and Hideaki Takahashi and Yutaro Kimura and Yoshiko Shigeyasu and Tetsuya Tsukamoto and Naozumi Hashimoto and Kazuyoshi Imaizumi",

note = "Publisher Copyright: {\textcopyright} 2024 The Japanese Respiratory Society",

year = "2024",

month = may,

doi = "10.1016/j.resinv.2024.03.002",

language = "English",

volume = "62",

pages = "438--441",

journal = "Respiratory Investigation",

issn = "2212-5345",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Autopsy case

T2 - Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19

AU - Moriya, Ryoma

AU - Kamihata, Naoki

AU - Niwa, Yoshikazu

AU - Kako, Hisashi

AU - Takahashi, Hideaki

AU - Kimura, Yutaro

AU - Shigeyasu, Yoshiko

AU - Tsukamoto, Tetsuya

AU - Hashimoto, Naozumi

AU - Imaizumi, Kazuyoshi

PY - 2024/5

Y1 - 2024/5

N2 - A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients. Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.

AB - A 51-year-old man with advanced lung cancer underwent chemotherapy including an immune checkpoint inhibitor (ICI). Subsequently, he developed ICI-related pneumonitis and colitis, followed by a ten-month treatment course of high doses of steroids. An infection with the SARS-CoV-2 Omicron BA.5 variant caused lethal respiratory failure. Autopsy examination revealed no evidence of viable lung cancer cells in the evaluated organs including the lungs, suggesting that pathological complete response (pCR) could be successfully achieved by ICI treatment in advanced lung cancer patients. Recognizing steroid-resistant ICI-related adverse events as critical factors in severe COVID-19 emphasizes the need for appropriate assessment of ICI-induced pCR.

UR - http://www.scopus.com/inward/record.url?scp=85188536027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85188536027&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2024.03.002

DO - 10.1016/j.resinv.2024.03.002

M3 - Article

C2 - 38518583

AN - SCOPUS:85188536027

SN - 2212-5345

VL - 62

SP - 438

EP - 441

JO - Respiratory Investigation

JF - Respiratory Investigation

IS - 3

ER -

Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this